Transcode Therapeutics Inc (RNAZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -16,755 | -10,839 | -8,518 | -3,327 | -18,546 |
| Depreciation Amortization | 535 | 412 | 285 | 142 | 517 |
| Other Working Capital | -352 | -1,294 | 629 | -935 | -1,082 |
| Other Operating Activity | 3,236 | 1,531 | 1,327 | 183 | 1,037 |
| Operating Cash Flow | $-13,336 | $-10,190 | $-6,277 | $-3,937 | $-18,075 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -22 | -21 | -8 | -4 | -36 |
| Investing Cash Flow | $-22 | $-21 | $-8 | $-4 | $-36 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 16,401 | 9,319 | 6,872 | 6,087 | 15,909 |
| Financing Cash Flow | $16,401 | $9,319 | $6,872 | $6,087 | $15,909 |
| Beginning Cash Position | 2,768 | 2,768 | 2,768 | 2,768 | 4,968 |
| End Cash Position | 5,811 | 1,876 | 3,355 | 4,914 | 2,768 |
| Net Cash Flow | $3,044 | $-892 | $587 | $2,146 | $-2,201 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,336 | -10,190 | -6,277 | -3,937 | -18,075 |
| Capital Expenditure | -22 | -21 | -8 | -4 | -36 |
| Free Cash Flow | -13,358 | -10,211 | -6,285 | -3,941 | -18,110 |